Climb Bio CLYM

Climb Bio, Inc. is a clinical stage biotechnology company developing therapeutics for immune mediated diseases. The company’s lead product candidate, budoprutug, is an anti CD19 monoclonal antibody being evaluated in primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. A second candidate, CLYM116, is an anti APRIL monoclonal antibody designed for IgA nephropathy and other B cell mediated disorders. Climb Bio holds worldwide rights to develop and commercialize budoprutug for all non oncology indications and has rights to CLYM116 outside of Greater China.

Revenue is generated primarily from upfront licensing fees, milestone payments, and royalties under collaboration and acquisition agreements. For example, the Mabworks agreement provided an upfront payment of $9.0 million and includes up to $30.0 million in development milestones, up to $832.0 million in commercial milestones, and tiered royalties on net sales. Additional potential milestone obligations arise from the Tenet acquisition and related agreements with Acelyrin and CRH.

Climb Bio occupies an early stage position in the competitive landscape of immune mediated disease therapeutics. For its budoprutug program, competitors include Amgen with its approved anti CD19 therapy Uplizna, AbbVie, Cullinan Therapeutics, Zenas BioPharma, Roche, Merck, Novartis, Bristol Myers Squibb, Cabaletta Bio, Kyverna Therapeutics, and Nkarta. For the CLYM116 program, rivals consist of Otsuka Pharmaceutical with its approved sibeprenlimab, Novartis, Jade Biosciences, Vertex Pharmaceuticals, and Vera Therapeutics. The company seeks to differentiate through budoprutug’s high affinity for CD19, low fucosylated Fc region enhancing effector function, and potential subcutaneous formulation offering convenient dosing. CLYM116 aims to stand out with its sweeper mechanism that promotes APRIL degradation and antibody recycling, a high affinity pH dependent binding profile, and Fc engineering for extended half life without effector function. Additionally, budoprutug has received orphan drug designation for primary membranous nephropathy, providing potential market exclusivity upon approval.

The company serves patients suffering from immune mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, systemic lupus erythematosus, and IgA nephropathy. Its customers include healthcare providers, hospitals, and clinics that administer the therapies. No specific customer names are disclosed in the filing.